MENU
Our pipeline of immune-modulating, clinical-stage product candidates are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation.
| Program & Target | Therapeutic Area | Preclinical | Phase 1 | Phase 2 | Phase 3 | Mkt | Rights | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Rilonacept IL-1α & IL-1β | Recurrent pericarditis (breakthrough therapy designation) |
Mid Phase 3 | Worldwide (excluding the Middle East and North Africa) | |||||||
| Mavrilimumab GM-CSFRα | Giant cell arteritis | Phase 2 | Worldwide | |||||||
| Relapsed or refractory |
End Phase 1 | Worldwide | ||||||||
| KPL-716 OSMRβ | Prurigo nodularis | Phase 2 | Worldwide | |||||||
| Multi-indication pilot study in diseases with a chronic pruritic component | Phase 2 | Worldwide | ||||||||
| KPL-404 CD40 | T-cell dependent, B-cell–mediated indications | Phase 1 | Worldwide | |||||||
